BLK

At the October 26 close of $1,127.66 the shares trade at 25.68x trailing earnings, 19.49x the FY2026 consensus of $57.859 and 17.40x the FY2027 consensus of $64.826, which reconciles to the supplied forward multiple of 17.3952 and to $1,127.66 divided by $64.826. Price-to-book is 3.03x and price-to-sales 6.42x against 19.1% revenue growth and 25.4% earnings growth, producing a supplied PEG of 0.9271 that improved from roughly 1.00 a week ago purely because the price fell while estimates rose; EV/EBITDA of 15.07 is a moderate profitability-adjusted multiple for a capital-light fee compounder, though no sector peer set is supplied so it cannot be benchmarked. The equity-risk compensation is thin on the near year: a 5.75% FY2027 earnings yield against a 4.986% 10-year Treasury is about 0.76 percentage points, but on FY2026's $57.859 the earnings yield is 5.13%, only 0.15 points, so almost the entire cushion depends on the out-year being delivered. At the $1,351 mean target the stock would trade near 20.84x FY2027 and at the $1,250 low target near 19.28x, which defines the multiple ceiling the sell-side is implicitly underwriting. Note the bundle's own inconsistency: enterprise value of $180.93 billion is below the $183.22 billion market cap despite $1.125 billion of net debt, producing an EV/market-cap of 0.99 that should arithmetically be about 1.006. Honest conclusion: fairly valued with a defensible sub-1.0 PEG and a modest discount to the analyst floor, but not statistically cheap, and the multiple rests on an earnings growth rate the bundle does not decompose into organic flows, asset mix and realized fee rates.

The October 26 close of $1,127.66 sits 3.09% above the SMA20 at $1,093.93, 3.02% above the EMA50 at $1,094.60 and 5.92% above the EMA200 at $1,064.66. The EMA50 is 2.81% above the EMA200, so golden-cross alignment is intact and slowly widening, with no crossover or death-cross risk visible in the 30-session sample. The path since September 2 is a decline to the September 16 low of $1,017.46, a basing range through late September and early October between roughly $1,040 and $1,092, then a sharp post-earnings expansion; the shares are 10.83% above that low and 5.01% below the $1,187.17 52-week high, at the 77.94th percentile of the 52-week range and 22.92% above the $917.39 52-week low. The key structural detail is that Friday's break of the $1,121.54 October 19 low was reversed on Monday, so the intermediate uptrend is intact, but the October 22 rejection at $1,159.99 after clearing the $1,150.21 October 20 high remains unabsorbed supply and the reclaim has not been validated by volume.

Q3 2026 EPS was $15.93 versus $14.30 consensus, a $1.63 or 11.39% beat, the largest of the seven supplied quarters and the seventh consecutive beat, with year-over-year EPS growth accelerating to 37.9% from 15.4% in June and 10.9% in March and an average surprise across the seven quarters of about 9.1%; post-print the shares rallied from $1,073.79 on October 14 to $1,149.60 on October 21, rejected $1,159.99 intraday on October 22, broke to $1,118.25 on October 23 and reclaimed $1,127.66 on October 26, but net-flow, fee-rate, free-cash-flow and ROE data remain absent so the organic quality of the beat still cannot be separated from market appreciation.

The post-earnings estimate revision cycle, anchored by TD Cowen's October 20 upgrade to Buy from Hold and target lift to $1,405 from $1,212, is the highest-impact fundamental item because it is the first formal rating change in 90 days, it raised the floor of the entire target distribution to $1,250, and it validates the 11.39% EPS beat and the 30-day markup in FY2026 estimates that underpin the 17.40x forward multiple; the most immediate price-moving factor, however, remains the unresolved $1,134.78-$1,159.99 supply band, which the October 26 bounce approached but did not test on convincing volume.

VIX at 18.39 sits in the middle of the neutral band and the 10-year eased to 4.986%, a modest relief for a 1.42-beta asset manager, but a rate near 5% still caps multiple expansion and leaves the FY2026 earnings-yield spread at roughly 0.15 points.

BlackRock is a scale-advantaged, capital-light fee platform with a 48.28% gross margin, 37.90% operating margin, 42.06% EBITDA margin, 24.22% net margin, debt-to-equity of 23.19%, only $1.125 billion of net debt against a $183.22 billion market cap and a 2.05% dividend that is up 10% year over year. The iShares franchise, the pending ETF share-class filings on five active U.S. mutual funds and the institutional distribution footprint are expensive to replicate, which supports a High thesis-durability rating. It is a market-linked compounder rather than a defensive asset: revenue and performance fees move with asset levels and the multiple moves with rates, so a 1.421 beta, 21.96% 20-day realized volatility and a 2.29% daily ATR are the ordinary cost of ownership. It belongs in the Core Growth sleeve at moderate size, sized around rate shocks and quarterly earnings rather than treated as a low-volatility anchor or a tactical trade.